(Approval lapsed) Clopidogrel 75mg tablets, USP (USA)
Section 19A approved medicine
(Approval lapsed) Clopidogrel 75mg tablets, USP (USA)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
PLAVIX clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack - ARTG 78622
CLOPIDOGREL GH clopidogrel (as besilate) 75mg film-coated tablet - ARTG 164870
CLOPIDOGREL GH clopidogrel (as besilate) 75mg film-coated tablet - ARTG 164870
Indication(s)
Prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with history of symptomatic atherosclerotic disease.
Acute Coronary Syndrome
Clopidogrel is indicated in combination with aspirin for patients with:
- Unstable angina or non-ST-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia).
- Clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or PCI, with or without stent).
- ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, Clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.